Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Recent Articles in News & Analysis

CR Sanjiu Buys 28% of Tasly Pharma for $869 Million
Aug 5, 2024

China Resources Sanjiu Medical & Pharmaceutical will buy a 28% stake in Tianjin’s Tasly Pharma Group for $869 million. Both companies make traditional Chinese medicines and pharmaceutical products, but Tasly also develops biologic medications through a subsidiary, Tasly Biopharma. Although CR Sanjiu will own only 28% of Tasly, the company said it would become Tasly’s controlling shareholder. Tasly Great Health will also transfer 5% of Tasly’s shares to CR Sanjiu's major shareholder, Guoxin Investment. CR Sanjiu is one of many companies that are a part of China Resources Corporation, a state-owned entity. More details....

Share this with colleagues:  

Kyowa Kirin Changes Focus, Sells China Operations for $105 Million
Aug 5, 2024

Tokyo’s Kyowa Kirin will turn its research focus to unmet needs in the areas of bone and mineral, hematologic cancers/intractable hematologic diseases and rare diseases. The company will form a global research organization to develop advanced antibody technologies and hematopoietic stem cell gene therapies (HSC-GT) in these areas. Kyowa will transfer its Chinese operations, including five established brands, to Hong Kong’s WinHealth Pharma for $105 million. More details....

Share this with colleagues:  

Week in Review: ImmuneOnco Out-licenses Two Antibodies in $2 Billion Deal
Aug 3, 2024

Deals and Financings

  • Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas for $2 billion;
  • Shanghai announced it would invest US$14 billion to support the growth of companies in biopharmaceuticals, AI and integrated circuits;
  • Japan’s Otsuka Pharmaceutical acquired Jnana Therapeutics, a Boston pharma with a rare disease candidate, for $800 million plus up to $325 million in milestones;
  • Biocytogen Pharma (Beijing) has granted an option for its B7H3/PTK7 BsADC to Ideaya Biosciences in an agreement worth up to $406 million;
  • Sirnaomics, a Suzhou-Maryland siRNA company, has formed a JV, Sagesse Bio, to develop its RNAi products as aesthetic medicines;
  • LTZ Therapeutics, a Shenzhen-Redwood City, CA immunotherapy biotech, completed a Series A financing of over $20 million;
  • Shenzhen Synthetica Pioneering closed a Series A round to develop novel living bacterial therapeutics;
  • Suzhou Porton Advanced Solutions and Guangzhou Geneseed Biotech agreed to combine their circRNA gene therapy services for CDMO clients;

CRO/CDMO

  • WuXi AppTec, a China CRDMO, announced “steady” earnings for the first half of 2024 despite the US Congress’s attempt to ban US biopharmas from doing business with WuXi;

Trials and Approvals

  • Yantai Luye Pharma was approved for a US launch of Erzofri®, a once-monthly extended release drug for schizophrenia and schizoaffective disorder.

    Share this with colleagues:  

ImmuneOnco Sells Rights for Two Assets to Instil in $2 Billion Deal
Aug 2, 2024

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio (NSDQ: TIL) of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million and up to more than $2 billion in milestones, plus royalties. Instil will have rights to ImmuneOnco’s proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M. ImmuneOnco has started a combination trial of the two candidates. Instil, an in-licensing company, has stopped development of its previous assets in recent years. More details....

Share this with colleagues:  

Sirnaomics Forms siRNA Joint Venture for Aesthetic Therapies
Aug 1, 2024

Sirnaomics, a Suzhou-Maryland siRNA company, has formed a JV, Sagesse Bio, with Gore Range Capital of Dallas to develop Sirnaomics’ RNAi products as aesthetic medicines. Sirnaomics will receive milestone payments of up to $33 million. It will eventually own a majority stake in Sagesse Bio worth $36 million after Gore Range completes a financing. Initially, Sagesse will start clinical evaluation of its candidate, SGY-101, a new designation of Sirnaomics’ lead siRNA candidate that has already started clinical trials for oncology and fat remodeling. More details....

Share this with colleagues:  

More Articles >>
Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here